Dyskeratosis CongenitaSymptoms, Doctors, Treatments, Advances & More
Dyskeratosis Congenita Overview
Learn About Dyskeratosis Congenita
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Office
Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is rated as an Elite provider by MediFind in the treatment of Dyskeratosis Congenita. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).
Fabian Beier practices practicing medicine in Aachen, Germany. Mr. Beier is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Anemia, Acquired Amegakaryocytic Thrombocytopenia, and Bone Marrow Transplant.
Tim Brummendorf practices practicing medicine in Aachen, Germany. Mr. Brummendorf is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Dyskeratosis Congenita, Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant.
Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-...
Summary: The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main questions it aims to answer are: * Is the therapy safe with tolerable side effects in patients with telomere biology disorders? * Are problems with the bone marrow or blood or lungs changed after 6 months of dC+dT treatmen...